Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM

The cardiorenal benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) are established, whereas those in patients without T2DM are not established. We sought to assess the cardiorenal efficacy and safety of SGLT2 inhibitors in non-T2DM patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lu-Feng, Ding, Liang-Liang, Zhan, Ze-Lin, Qiu, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277944/
https://www.ncbi.nlm.nih.gov/pubmed/34277737
http://dx.doi.org/10.3389/fcvm.2021.690529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277944/
https://www.ncbi.nlm.nih.gov/pubmed/34277737
http://dx.doi.org/10.3389/fcvm.2021.690529

Ejemplares similares